Suk‐Woo Yang

568 citations
37 papers · 367 indexed · h-index 11
Topics
Lymphoma Diagnosis and Treatment (11 papers)Vascular Tumors and Angiosarcomas (8 papers)CNS Lymphoma Diagnosis and Treatment (8 papers)
Partner nations
South KoreaUnited States

In The Last Decade

Suk‐Woo Yang

35 papers receiving 357 citations

Peers

Suk‐Woo Yang
Comparison fields: 5 of 42
  • Pathology and Forensic Medicine 154
  • Surgery 141
  • Neurology 128
  • Dermatology 98
  • Genetics 94
Replace Peter S. Levin with:
Peter S. Levin United States
Dan DeAngelis Canada
Hossein Salour Iran
Adel H. Alsuhaibani Saudi Arabia
Thomas A. Bersani United States
Bryan Arthurs Canada
Kaveh Vahdani United Kingdom
Bernard Chang United Kingdom
Chee‐Chew Yip Singapore
Lih Ma Taiwan
Suk‐Woo Yang relative to Peter S. Levin United States Peter S. Levin's profile →
Citations per field
00.5×6.3×
Peter S. Levin · 1×
Citations per year

Countries citing papers authored by Suk‐Woo Yang

Since Specialization
Citations

This map shows the geographic impact of Suk‐Woo Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suk‐Woo Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suk‐Woo Yang more than expected).

Fields of papers citing papers by Suk‐Woo Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suk‐Woo Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suk‐Woo Yang. The network helps show where Suk‐Woo Yang may publish in the future.

Co-authorship network of co-authors of Suk‐Woo Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Suk‐Woo Yang. A scholar is included among the top collaborators of Suk‐Woo Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suk‐Woo Yang. Suk‐Woo Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 2
3 2
4 1
5 5
6 2
7 2
8 12
9 2
10 3
11 4
12 7
13 23
14 25
15 29
16 64
17 7
18 4
19 36
20 19

About Suk‐Woo Yang

Suk‐Woo Yang is a scholar working on Pathology and Forensic Medicine, Dermatology and Ophthalmology, having authored 37 papers that have together received 367 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (11 papers), Vascular Tumors and Angiosarcomas (8 papers) and CNS Lymphoma Diagnosis and Treatment (8 papers). The work is most often cited by research in Dermatology (98 citations), Ophthalmology (90 citations) and Pathology and Forensic Medicine (154 citations). Suk‐Woo Yang has collaborated with scholars based in South Korea and United States. Frequent co-authors include Jisun Paik, Won‐Kyung Cho, Su Kyung Jung, Won‐Kyung Cho, Seok‐Goo Cho, Kyong Jin Cho, Byung‐Ock Choi, Sung‐Eun Lee, Seung Eun Jung and Sung‐Hoon Kim. Their work appears in journals such as PLoS ONE, British Journal of Ophthalmology and Oncotarget.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026